WHWolfgang Härtig

Wolfgang Härtig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wolfgang Härtig has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Jens Grosche

    Effigos GmbH, Am Deutschen Platz 4, 04103 Leipzig, Germany

    6 shared publications
  • Dominik Michalski

    Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany

    3 shared publications
  • Jens Stieler

    Department of Molecular and Cellular Mechanisms of Neurodegeneration, Paul Flechsig Institute of Brain Research, University of Leipzig, Leipzig, Germany

    3 shared publications
  • Thomas Arendt

    Departments of Neurochemistry and Neuroanatomy, Paul Flechsig Institute for Brain Research, University of Leipzig, Jahnallee 59, 04109 Leipzig, Germany

    3 shared publications
  • Ate S. Boerema

    Department of Molecular Neurobiology, Groningen, Institute of Evolutionary Life Science (GELIFES), University of Groningen, Groningen, The Netherlands

    2 shared publications
  • Oliver Wirths

    Department of Psychiatry and Psychotherapy, University Medical Center Göttingen (UMG)

    2 shared publications

Latest Publications

  • Open Access

    Update on Perineuronal Net Staining With Wisteria floribunda Agglutinin (WFA)

    by Wolfgang Härtig, Anton Meinicke, Dominik Michalski, Stefan Schob, Carsten Jäger

    As chemically specialized forms of the extracellular matrix in the central nervous system, polyanionic perineuronal nets (PNs) contain diverse constituents, including chondroitin sulfate proteoglycans (CSPGs), hyaluronic acid, and tenascins. They are detectable by various histological approaches such as colloidal iron binding and immunohistochemical staining to reveal, for instance, the CSPGs aggrecan, neurocan, phosphacan, and versican. Moreover, biotin, peroxidase, or fluorescein conjugates of the lectins Vicia villosa agglutinin and soybean agglutinin enable the visualization of PNs. At present, the N-acetylgalactosamine-binding Wisteria floribunda agglutinin (WFA) is the most widely applied marker for PNs. Therefore, this article is largely focused on methodological aspects of WFA staining. Notably, fluorescent WFA labeling allows, after its conversion into electron-dense adducts, electron microscopic analyses. Furthermore, the usefulness of WFA conjugates for the oftentimes neglected in vivo and in vitro labeling of PNs is emphasized. Subsequently, we discuss impaired WFA-staining sites after long-lasting experiments in vitro, especially in autoptic brain samples with long postmortem delay and partial enzymatic degradation, while immunolabeling of aggrecan and CSPG link proteins under such conditions has proven more robust. In some hippocampal regions from perfusion-fixed mice, more PNs are aggrecan immunoreactive than WFA positive, whereas the retrosplenial cortex displays many WFA-binding PNs devoid of visible aggrecan immunoreactivity. Additional multiple fluorescence labeling exemplarily revealed in ischemic tissue diminished staining of WFA-binding sites and aquaporin 4 and concomitantly upregulated immunolabeling of neurofilament, light chains, and collagen IV. Finally, we briefly discuss possible future staining approaches based on nanobodies to facilitate novel technologies revealing details of net morphology.


  • Up-regulation of neurofilament light chains is associated with diminished immunoreactivities for MAP2 and tau after ischemic stroke in rodents and in a human case

    by Wolfgang Härtig, Martin Krueger, Sarah Hofmann, Hartmut Preißler, Martin Märkel, Clara Frydrychowicz, Wolf C. Mueller, Ingo Bechmann, Dominik Michalski


  • Immunolesion‐induced loss of cholinergic projection neurones promotes β‐amyloidosis and tau hyperphosphorylation in the hippocampus of triple‐transgenic mice

    by W. Härtig, A. Saul, J. Kacza, J. Grosche, S. Goldhammer, D. Michalski, O. Wirths

    Aims: Currently available animal models incompletely capture the complex pathophysiology of Alzheimer's disease (AD), typically involving β‐amyloidosis, neurofibrillary tangle formation and loss of basal forebrain cholinergic projection neurones (CPN). While age‐dependent β‐amyloidosis and tau hyperphosphorylation are mimicked in triple‐transgenic mice (3xTg), experimental induction of CPN loss in these mice is still lacking. Here, we introduce a more‐complex animal model of AD by inducing cellular loss of CPN in an already existing transgenic background aiming to elucidate subsequent changes of hippocampal β‐amyloid (Aβ) and tau pathology.Methods: Twelve‐month‐old 3xTg mice intracerebroventricularly received the rabbit‐anti‐low affinity neurotrophin receptor p75‐saporin, an immunotoxin specifically targeting forebrain CPN. After histochemical verification of immunolesion in immersion‐fixed forebrains, markers of Aβ and tau metabolism were analysed using quantitative Western blot analyses of hippocampi from these mice. In parallel, these markers and glial activation were investigated by multiple immunofluorescence labelling of perfusion‐fixed hippocampi and confocal laser‐scanning microscopy.Results: Four months after immunolesion, the selective lesion of CPN was verified by disappearance of choline acetyltransferase and p75 immunolabelling. Biochemical analysis of hippocampi from immunolesioned mice revealed enhanced levels of Aβ, amyloid precursor protein (APP) and its fragment C99. Furthermore, immunolesion‐induced increase in levels of phospho‐tau and tau with AD‐like conformation were seen in 16‐month‐old mice. Immunofluorescence staining confirmed an age‐dependent occurrence of hippocampal Aβ‐deposits and phospho‐tau, and demonstrated drastic gliosis around Aβ‐plaques after immunolesion.Conclusion: Overall, this extended model promises further insights into the complexity of AD and contributes to novel treatment strategies also targeting the cholinergic system.


  • Open Access

    Autonomic reactions and peri-interventional alterations in body weight as potential supplementary outcome parameters for thromboembolic stroke in rats

    by Dominik Michalski, Christopher Weise, Carsten Hobohm, Lea Küppers-Tiedt, Johann Pelz, Dietmar Schneider, Johannes Kacza, Wolfgang Härtig

    Since several neuroprotectives failed to reproduce promising preclinical results under clinical conditions, efforts emerged to implement clinically relevant endpoints in animal stroke studies. Thereby, insufficient attention was given on autonomic reactions due to experimental stroke, although clinical trials reported on high functional and prognostic impact. This study focused on autonomic consequences and body weight changes in a translational relevant stroke model and investigated interrelations to different outcome measurements.


  • In vivo labelling of hippocampal β‐amyloid in triple‐transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles

    by Wolfgang Härtig, Johannes Kacza, Bernd‐Reiner Paulke, Jens Grosche, Ute Bauer, Anke Hoffmann, Paul W. Elsinghorst, Michael Gütschow

    The drastic loss of cholinergic projection neurons in the basal forebrain is a hallmark of Alzheimer’s disease (AD), and drugs most frequently applied for the treatment of dementia include inhibitors of the acetylcholine‐degrading enzyme acetylcholinesterase (AChE). This protein is known to act as a ligand of β‐amyloid (Aβ) in senile plaques, a further neuropathological sign of AD. Recently, we have shown that the fluorescent, heterodimeric AChE inhibitor PE154 allows for the histochemical staining of cortical Aβ plaques in triple‐transgenic (TTG) mice with age‐dependent β‐amyloidosis and tau hyperphosphorylation, an established animal model for aspects of AD. In the present study, we have primarily demonstrated the targeting of Aβ‐immunopositive plaques with PE154 in vivo for 4 h up to 1 week after injection into the hippocampi of 13–20‐month‐old TTG mice. Numerous plaques, double‐stained for PE154 and Aβ‐immunoreactivity, were revealed by confocal laser‐scanning microscopy. Additionally, PE154 targeted hippocampal Aβ deposits in aged TTG mice after injection of carboxylated polyglycidylmethacrylate nanoparticles delivering the fluorescent marker in vivo. Furthermore, biodegradable core‐shell polystyrene/polybutylcyanoacrylate nanoparticles were found to be suitable, alternative vehicles for PE154 as a useful in vivo label of Aβ. Moreover, we were able to demonstrate that PE154 targeted Aβ, but neither phospho‐tau nor reactive astrocytes surrounding the plaques. In conclusion, nanoparticles appear as versatile carriers of AChE inhibitors and other promising drugs for the treatment of AD.


  • Triple fluorescence labelling of neuronal, glial and vascular markers revealing pathological alterations in various animal models

    by Wolfgang Härtig, Andreas Reichenbach, Cornelia Voigt, Johannes Boltze, Larysa Bulavina, Martin U. Schuhmann, Johannes Seeger, Gerald F. Schusser, Christiane Freytag, Jens Grosche


  • Hibernation model of tau phosphorylation in hamsters: selective vulnerability of cholinergic basal forebrain neurons – implications for Alzheimer's disease

    by Wolfgang Härtig, Jens Stieler, Ate S. Boerema, Jennifer Wolf, Udo Schmidt, Jana Weißfuß, Torsten Bullmann, Arjen M. Strijkstra, Thomas Arendt

    Neurofibrillar tangles made up of ‘paired helical filaments’ (PHFs) consisting of hyperphosphorylated microtubule‐associated protein tau are major hallmarks of Alzheimer's disease (AD). Tangle formation selectively affects certain neuronal types and systematically progresses throughout numerous brain areas, which reflects a hierarchy of neuronal vulnerability and provides the basis for the neuropathological staging of disease severity. Mechanisms underlying this selective neuronal vulnerability are unknown. We showed previously that reversible PHF‐like phosphorylation of tau occurs during obligate hibernation. Here we extend these findings to facultative hibernators such as Syrian hamsters (Mesocricetus auratus) forced into hibernation. In this model, we showed in the basal forebrain projection system that cholinergic neurons are selectively affected by PHF‐like phosphorylated tau, while γ‐aminobutyric acid (GABA)ergic neurons are largely spared, which shows strong parallels to the situation in AD. Formation of PHF‐tau in these neurons apparently does not affect their function as pacemaker for terminating hibernation. We conclude that although formation of PHF‐like phosphorylated tau in the mammalian brain follows a certain hierarchy, affecting some neurons more frequently than others, it is not necessarily associated with impaired neuronal function and viability. This indicates a more general link between PHF‐like phosphorylation of tau and the adaptation of neurons under conditions of a ‘vita minima’.


  • Simultaneous detection of tau phospho-epitopes with haptenylated antibodies

    by Wolfgang Härtig, Jörg Lehmann, Jens Stieler, David Singer, Jens Grosche, Thomas Arendt, Ralf Hoffmann

    Neurofibrillary tangles as a neuropathological hallmark of Alzheimer's disease are mainly composed of abnormally phosphorylated microtubule-associated protein tau. The present work was primarily focused on the immunohistochemical characterization of recently developed monoclonal antibodies directed against disease-associated epitopes. Anti-phospho-threonine 212/phospho-serine 214 (HPT-1), anti-phospho-threonine 231/phospho-serine 235 (HPT-101) and their biotinylated derivatives were shown to be sensitive markers for the immunohistochemical detection of neuropathological alterations during Alzheimer's disease. Triple carbocyanine immunofluorescence labelling was based on digoxigenylated, fluoresceinated and biotinylated primary antibodies. AT8-immunolabelling of phospho-serine 202 and phospho-threonine 205 combined with HPT-1 and HPT-101-staining revealed similar distribution patterns of the three double-phosphorylated tau epitopes in the neocortex of patients with Alzheimer's disease.